Citi raised the firm’s price target on Neurocrine (NBIX) to $203 from $175 and keeps a Buy rating on the shares following the Q3 beat. The firm says Crenessity significantly outperformed expectations in Q3 and is positioned to be a blockbuster.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine’s Strong Financial Performance and Growth Potential Justify Buy Rating
- Neurocrine Biosciences Reports Strong Q3 2025 Growth
- Neurocrine’s Strong Q3 Performance and Growth Potential Justify Buy Rating
- Neurocrine’s Strong Performance and Strategic Initiatives Drive Buy Rating
- Neurocrine reports Q3 adjusted EPS $2.17, consensus $2.07